Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder.
Nine patients with in situ bladder cancer (TIS) were treated by intravesical instillation of epi-doxorubicin (epi-DOX). The amount of anthracycline in 1 ml plasma was in the nanogram range. 78.9 +/- 12.0% and 84.2 +/- 10.6% of the administered dose (30 and 50 mg, respectively) could be recovered.
D000042:Absorption; D000283:Administration, Intravesical; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D015251:Epirubicin; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D015251:Epirubicin; D004317:Doxorubicin